MisterBlues schreef op 28 augustus 2020 11:27:
Bachem Holding AG (Ticker: BANB:SIX)Currently the Aviptadil, both IV and Inhaled form, are manufactured by Bachem Holding AG, listed on Swiss Stock exchange.
Market Cap. CHF$5.13B, 2020 Forward PE 80x.
www.nejm.org/doi/10.1056/NEJMc2000343you have to register to see the article. researchers are using Inhaled form Aviptadil (produced by Bachem AG) to treat lung cancer patient with adverse immune-related symptoms.
Aviptadil showed promising sign to outperform an extremely expensive and profitable drug by Merk, called Pembrolizumab or Keytruda, which is a PD-1 Inhibitor to treat different cancers.